Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Acelrx Pharmaceuticals Inc (ACRX)  
$1.08 0.07 (6.09%) as of 4:30 Fri 5/17


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 8,200,000
Market Cap: 8.86(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.463 - $1.47
Level I Sector: Conglomerates
Level II Sector: Conglomerates
Level III Sector: Conglomerates

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Co.'s sufentanil sublingual products and product candidates include DSUVIA®, which is indicated for use in adults in supervised healthcare settings; Zalviso®, which is intended for the management of moderate-to-severe acute pain in hospitalized adult patients; and ARX-02, which is for cancer breakthrough pain in opioid-tolerant patients.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 10,000 20,000 66,400
Total Buy Value $0 $7,268 $15,218 $25,551
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 2 3
Total Shares Sold 0 0 16,956 16,956
Total Sell Value $0 $0 $19,235 $19,235
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 2 2
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 271
  Page 10 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hamel Lawrence G Chief Development Officer   •       –      –    2013-09-17 4 D $10.71 $10,710 D/D (1,000) 30,708     -
   Hamel Lawrence G Chief Development Officer   •       –      –    2013-09-17 4 A $1.20 $5,324 D/D 4,437 31,708     -
   Nohra Guy P Director   –       •      –    2013-09-17 4 AS $10.48 $523,107 I/I (49,921) 2,728,588     -
   Nohra Guy P Director   –       •      –    2013-09-16 4 AS $10.75 $176,221 I/I (16,398) 2,778,509     -
   Perceptive Life Sciences Master Fund Ltd 10% Owner   –       –       •   2013-07-23 4 B $11.65 $9,902,500 I/I 850,000 5,858,400 1.5     -
   Edwards Mark G Director   –       •      –    2013-06-06 4 B $8.10 $81,000 D/D 10,000 60,000 2.39     -
   Adams Adrian Director   –       •      –    2013-05-28 4 B $8.39 $419,500 D/D 50,000 75,000 2.39     -
   Adams Adrian Director   –       •      –    2013-05-24 4 B $7.78 $194,500 D/D 25,000 25,000 2.39     -
   Hamel Lawrence G Chief Development Officer   •       –      –    2013-03-02 4 D $4.96 $7,683 D/D (1,549) 26,578     -
   Dasu Badri N Chief Engineering Officer   •       –      –    2013-03-02 4 D $4.96 $6,760 D/D (1,363) 18,139     -
   Edelman Joseph 10% Owner   –       –       •   2012-12-07 3 IO $0.00 $0 I/I 0 5,008,400     -
   Three Arch Associates Iv Lp 10% Owner   –       –       •   2012-12-07 4 B $3.31 $7,999,999 I/I 2,416,918 139,621 1.5     -
   Freund John Gordon 10% Owner   –       –       •   2012-05-29 4 B $3.40 $967,973 I/I 284,698 4,161,933 1.5     -
   Three Arch Associates L P 10% Owner   –       –       •   2012-05-29 4 B $3.40 $967,973 I/I 284,698 87,408 1.5     -
   Hamel Lawrence G Chief Development Officer   •       –      –    2012-03-02 4 D $2.91 $4,996 D/D (1,717) 13,643     -
   Welch James H Chief Financial Officer   •       –      –    2011-09-07 4 B $3.39 $10,179 D/D 3,000 15,000 2.74     -
   Welch James H Chief Financial Officer   •       –      –    2011-09-06 4 B $3.32 $23,238 D/D 7,000 12,000 2.74     -
   Hamel Lawrence G Chief Development Officer   •       –      –    2011-09-02 4 D $3.10 $4,771 D/D (1,539) 15,360     -
   Dasu Badri N Chief Engineering Officer   •       –      –    2011-09-02 4 D $3.10 $4,197 D/D (1,354) 13,517     -
   Schreck Thomas A Director   –       •      –    2011-08-29 4 B $3.28 $1,640 I/I 500 17,982 2.02     -
   Schreck Thomas A Director   –       •      –    2011-08-29 4 B $3.27 $1,634 D/D 500 300,951 2.31     -
   Schreck Thomas A Director   –       •      –    2011-08-24 4 B $3.01 $3,010 I/I 1,000 17,482 2.1     -
   Schreck Thomas A Director   –       •      –    2011-08-24 4 B $3.01 $3,010 D/D 1,000 300,451 2.31     -
   Palmer Pamela P Chief Medical Officer   •       •      –    2011-06-09 4 B $4.61 $40,568 D/D 8,800 326,394 2.81     -
   King Richard Chief Executive Officer   •       •      –    2011-06-09 4 B $4.56 $15,960 D/D 3,500 126,957 2.81     -
  271 Records found
  Previous  10  11   
  Page 10 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us